You just read:

Zimmer Biomet Announces FDA Approval of Expanded 26-week Efficacy Claim for Gel-One® Cross-Linked Hyaluronate for Treatment of Pain Associated with Knee Osteoarthritis

News provided by

Zimmer Biomet Holdings, Inc.

Feb 01, 2017, 16:30 ET